News
![Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT): https://mms.businesswire.com/media/20191101005100/en/736004/5/Sangamo_logoTM.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNzhpRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--38b3f45f170b11880f9bbfb3e14c3e180b77ea27/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Sangamo_logoTM.jpg?locale=us)
Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 14 Sangamo abstracts for presentation at
![IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBenlNSlE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--44b7c2e9ec1d34b6817ce17f4c733565e4a558a7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/IMV_Logos_IMV-Logo_BrandStatement.jpg?locale=us)
IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives
IMV Inc. (the “Company” or “IMV”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat
![U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Childrenhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBZHc9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--be1a2af5756eaa0acf5414ead3504a7e3ad45f8a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Pfizer.jpg?locale=us)
U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PREVNAR 20® (20-valent Pneumococcal Conjugate Vaccine) for the prevention of invasive
![Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference: https://mms.businesswire.com/media/20220126005163/en/1338762/5/Silence-Logo-FINAL-rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1BjVnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--be75b7d9b4c0e9435a1d58c043c3c8d9b8f5a45e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Silence-Logo-FINAL-rgb.jpg?locale=us)
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
![Astellas Enters Into Definitive Agreement to Acquire Iveric Bio](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Astellas Enters Into Definitive Agreement to Acquire Iveric Bio
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and IVERIC Bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio, “Iveric Bio”) today announced that on April 29, 2023
![Xencor Appoints Nancy Valente, M.D., as Chief Development Officer: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNElsRUE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c4d0ef2109eb59269aca9850381b8fb5000d84e6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Xencor_RGB_fullcolor.jpg?locale=us)
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the
![Sensorion to participate in Chardan’s Annual Genetic Medicines & Cell Therapy Manufacturing Summit and Kempen’s Life Sciences Conference: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0dxVmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--df3db62501cd2dac51e6a4832a420790d1de65b6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/logo-sensorion2.jpg?locale=us)
Sensorion to participate in Chardan’s Annual Genetic Medicines & Cell Therapy Manufacturing Summit and Kempen’s Life Sciences Conference
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, is pleased to announce its participation
![EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
EQS-News: BB BIOTECH AG: Creating blockbuster drugs using algorithms
![Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
![EQS-News: Abivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
EQS-News: Abivax: Publication of an expert article in JCC on obefazimod as promising therapeutic management option for UC patients
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
![Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA™ Commercial Launch Progressing Ahead of Schedule
![Abivax postpones the publication of its 2023 Universal Registration Document](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Abivax postpones the publication of its 2023 Universal Registration Document
![Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![EQS-News: MPH Health Care AG: Preliminary IFRS result 2022](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
EQS-News: MPH Health Care AG: Preliminary IFRS result 2022
![EQS-News: Formycon publishes results for financial year 2022](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
EQS-News: Formycon publishes results for financial year 2022
![Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Convatec Group PLC: HOL-Holding(s) in Company](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Convatec Group PLC: HOL-Holding(s) in Company
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![EQS-News: Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
EQS-News: Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
![Evolva publishes timeline of the Reverse Stock Split](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Evolva publishes timeline of the Reverse Stock Split
![Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)